Ceramide-initiated protein phosphatase 2A activation contributes to arterial dysfunction in vivo

Leena P. Bharath, Ting Ruan, Youyou Li, Anindita Ravindran, Xin Wan, Jennifer Kim Nhan, Matthew Lewis Walker, Lance Deeter, Rebekah Goodrich, Elizabeth Johnson, Derek Munday, Robert Mueller, David Kunz, Deborah Jones, Van Reese, Scott A. Summers, Pon Velayutham Anandh Babu, William L. Holland, Quan Jiang Zhang, E. Dale AbelJ. David Symons

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Prior studies have implicated accumulation of ceramide in blood vessels as a basis for vascular dysfunction in diet-induced obesity via a mechanism involving type 2 protein phosphatase (PP2A) dephosphorylation of endothelial nitric oxide synthase (eNOS). The current study sought to elucidate the mechanisms linking ceramide accumulation with PP2A activation and determine whether pharmacological inhibition of PP2A in vivo normalizes obesity-associated vascular dysfunction and limits the severity of hypertension. We show in endothelial cells that ceramide associates with the inhibitor 2 of PP2A (I2PP2A) in the cytosol, which disrupts the association of I2PP2A with PP2A leading to its translocation to the plasma membrane. The increased association between PP2A and eNOS at the plasma membrane promotes dissociation of an Akt-Hsp90-eNOS complex that is required for eNOS phosphorylation and activation. A novel small-molecule inhibitor of PP2A attenuated PP2A activation, prevented disruption of the Akt-Hsp90-eNOS complex in the vasculature, preserved arterial function, and maintained normal blood pressure in obese mice. These findings reveal a novel mechanism whereby ceramide initiates PP2A colocalization with eNOS and demonstrate that PP2A activation precipitates vascular dysfunction in diet-induced obesity. Therapeutic strategies targeted to reducing PP2A activation might be beneficial in attenuating vascular complications that exist in the context of type 2 diabetes, obesity, and conditions associated with insulin resistance.

Original languageEnglish (US)
Pages (from-to)3914-3926
Number of pages13
JournalDiabetes
Volume64
Issue number11
DOIs
StatePublished - Nov 1 2015

Fingerprint

Protein Phosphatase 2
Nitric Oxide Synthase Type III
Ceramides
Blood Vessels
Obesity
Cell Membrane
Diet
Obese Mice
Cytosol
Type 2 Diabetes Mellitus
Insulin Resistance
Endothelial Cells
Phosphorylation
Pharmacology
Blood Pressure
Hypertension

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Bharath, L. P., Ruan, T., Li, Y., Ravindran, A., Wan, X., Nhan, J. K., ... Symons, J. D. (2015). Ceramide-initiated protein phosphatase 2A activation contributes to arterial dysfunction in vivo. Diabetes, 64(11), 3914-3926. https://doi.org/10.2337/db15-0244

Ceramide-initiated protein phosphatase 2A activation contributes to arterial dysfunction in vivo. / Bharath, Leena P.; Ruan, Ting; Li, Youyou; Ravindran, Anindita; Wan, Xin; Nhan, Jennifer Kim; Walker, Matthew Lewis; Deeter, Lance; Goodrich, Rebekah; Johnson, Elizabeth; Munday, Derek; Mueller, Robert; Kunz, David; Jones, Deborah; Reese, Van; Summers, Scott A.; Babu, Pon Velayutham Anandh; Holland, William L.; Zhang, Quan Jiang; Abel, E. Dale; Symons, J. David.

In: Diabetes, Vol. 64, No. 11, 01.11.2015, p. 3914-3926.

Research output: Contribution to journalArticle

Bharath, LP, Ruan, T, Li, Y, Ravindran, A, Wan, X, Nhan, JK, Walker, ML, Deeter, L, Goodrich, R, Johnson, E, Munday, D, Mueller, R, Kunz, D, Jones, D, Reese, V, Summers, SA, Babu, PVA, Holland, WL, Zhang, QJ, Abel, ED & Symons, JD 2015, 'Ceramide-initiated protein phosphatase 2A activation contributes to arterial dysfunction in vivo', Diabetes, vol. 64, no. 11, pp. 3914-3926. https://doi.org/10.2337/db15-0244
Bharath LP, Ruan T, Li Y, Ravindran A, Wan X, Nhan JK et al. Ceramide-initiated protein phosphatase 2A activation contributes to arterial dysfunction in vivo. Diabetes. 2015 Nov 1;64(11):3914-3926. https://doi.org/10.2337/db15-0244
Bharath, Leena P. ; Ruan, Ting ; Li, Youyou ; Ravindran, Anindita ; Wan, Xin ; Nhan, Jennifer Kim ; Walker, Matthew Lewis ; Deeter, Lance ; Goodrich, Rebekah ; Johnson, Elizabeth ; Munday, Derek ; Mueller, Robert ; Kunz, David ; Jones, Deborah ; Reese, Van ; Summers, Scott A. ; Babu, Pon Velayutham Anandh ; Holland, William L. ; Zhang, Quan Jiang ; Abel, E. Dale ; Symons, J. David. / Ceramide-initiated protein phosphatase 2A activation contributes to arterial dysfunction in vivo. In: Diabetes. 2015 ; Vol. 64, No. 11. pp. 3914-3926.
@article{8c21a28341464e8b90169be979710b0d,
title = "Ceramide-initiated protein phosphatase 2A activation contributes to arterial dysfunction in vivo",
abstract = "Prior studies have implicated accumulation of ceramide in blood vessels as a basis for vascular dysfunction in diet-induced obesity via a mechanism involving type 2 protein phosphatase (PP2A) dephosphorylation of endothelial nitric oxide synthase (eNOS). The current study sought to elucidate the mechanisms linking ceramide accumulation with PP2A activation and determine whether pharmacological inhibition of PP2A in vivo normalizes obesity-associated vascular dysfunction and limits the severity of hypertension. We show in endothelial cells that ceramide associates with the inhibitor 2 of PP2A (I2PP2A) in the cytosol, which disrupts the association of I2PP2A with PP2A leading to its translocation to the plasma membrane. The increased association between PP2A and eNOS at the plasma membrane promotes dissociation of an Akt-Hsp90-eNOS complex that is required for eNOS phosphorylation and activation. A novel small-molecule inhibitor of PP2A attenuated PP2A activation, prevented disruption of the Akt-Hsp90-eNOS complex in the vasculature, preserved arterial function, and maintained normal blood pressure in obese mice. These findings reveal a novel mechanism whereby ceramide initiates PP2A colocalization with eNOS and demonstrate that PP2A activation precipitates vascular dysfunction in diet-induced obesity. Therapeutic strategies targeted to reducing PP2A activation might be beneficial in attenuating vascular complications that exist in the context of type 2 diabetes, obesity, and conditions associated with insulin resistance.",
author = "Bharath, {Leena P.} and Ting Ruan and Youyou Li and Anindita Ravindran and Xin Wan and Nhan, {Jennifer Kim} and Walker, {Matthew Lewis} and Lance Deeter and Rebekah Goodrich and Elizabeth Johnson and Derek Munday and Robert Mueller and David Kunz and Deborah Jones and Van Reese and Summers, {Scott A.} and Babu, {Pon Velayutham Anandh} and Holland, {William L.} and Zhang, {Quan Jiang} and Abel, {E. Dale} and Symons, {J. David}",
year = "2015",
month = "11",
day = "1",
doi = "10.2337/db15-0244",
language = "English (US)",
volume = "64",
pages = "3914--3926",
journal = "Diabetes",
issn = "0012-1797",
publisher = "American Diabetes Association Inc.",
number = "11",

}

TY - JOUR

T1 - Ceramide-initiated protein phosphatase 2A activation contributes to arterial dysfunction in vivo

AU - Bharath, Leena P.

AU - Ruan, Ting

AU - Li, Youyou

AU - Ravindran, Anindita

AU - Wan, Xin

AU - Nhan, Jennifer Kim

AU - Walker, Matthew Lewis

AU - Deeter, Lance

AU - Goodrich, Rebekah

AU - Johnson, Elizabeth

AU - Munday, Derek

AU - Mueller, Robert

AU - Kunz, David

AU - Jones, Deborah

AU - Reese, Van

AU - Summers, Scott A.

AU - Babu, Pon Velayutham Anandh

AU - Holland, William L.

AU - Zhang, Quan Jiang

AU - Abel, E. Dale

AU - Symons, J. David

PY - 2015/11/1

Y1 - 2015/11/1

N2 - Prior studies have implicated accumulation of ceramide in blood vessels as a basis for vascular dysfunction in diet-induced obesity via a mechanism involving type 2 protein phosphatase (PP2A) dephosphorylation of endothelial nitric oxide synthase (eNOS). The current study sought to elucidate the mechanisms linking ceramide accumulation with PP2A activation and determine whether pharmacological inhibition of PP2A in vivo normalizes obesity-associated vascular dysfunction and limits the severity of hypertension. We show in endothelial cells that ceramide associates with the inhibitor 2 of PP2A (I2PP2A) in the cytosol, which disrupts the association of I2PP2A with PP2A leading to its translocation to the plasma membrane. The increased association between PP2A and eNOS at the plasma membrane promotes dissociation of an Akt-Hsp90-eNOS complex that is required for eNOS phosphorylation and activation. A novel small-molecule inhibitor of PP2A attenuated PP2A activation, prevented disruption of the Akt-Hsp90-eNOS complex in the vasculature, preserved arterial function, and maintained normal blood pressure in obese mice. These findings reveal a novel mechanism whereby ceramide initiates PP2A colocalization with eNOS and demonstrate that PP2A activation precipitates vascular dysfunction in diet-induced obesity. Therapeutic strategies targeted to reducing PP2A activation might be beneficial in attenuating vascular complications that exist in the context of type 2 diabetes, obesity, and conditions associated with insulin resistance.

AB - Prior studies have implicated accumulation of ceramide in blood vessels as a basis for vascular dysfunction in diet-induced obesity via a mechanism involving type 2 protein phosphatase (PP2A) dephosphorylation of endothelial nitric oxide synthase (eNOS). The current study sought to elucidate the mechanisms linking ceramide accumulation with PP2A activation and determine whether pharmacological inhibition of PP2A in vivo normalizes obesity-associated vascular dysfunction and limits the severity of hypertension. We show in endothelial cells that ceramide associates with the inhibitor 2 of PP2A (I2PP2A) in the cytosol, which disrupts the association of I2PP2A with PP2A leading to its translocation to the plasma membrane. The increased association between PP2A and eNOS at the plasma membrane promotes dissociation of an Akt-Hsp90-eNOS complex that is required for eNOS phosphorylation and activation. A novel small-molecule inhibitor of PP2A attenuated PP2A activation, prevented disruption of the Akt-Hsp90-eNOS complex in the vasculature, preserved arterial function, and maintained normal blood pressure in obese mice. These findings reveal a novel mechanism whereby ceramide initiates PP2A colocalization with eNOS and demonstrate that PP2A activation precipitates vascular dysfunction in diet-induced obesity. Therapeutic strategies targeted to reducing PP2A activation might be beneficial in attenuating vascular complications that exist in the context of type 2 diabetes, obesity, and conditions associated with insulin resistance.

UR - http://www.scopus.com/inward/record.url?scp=84946441531&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946441531&partnerID=8YFLogxK

U2 - 10.2337/db15-0244

DO - 10.2337/db15-0244

M3 - Article

C2 - 26253611

AN - SCOPUS:84946441531

VL - 64

SP - 3914

EP - 3926

JO - Diabetes

JF - Diabetes

SN - 0012-1797

IS - 11

ER -